Drug Trial Radar · NCT05765006
CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
24
Planned (sponsor's estimate)
Start
Feb 24, 2023
Primary completion
Dec 30, 2024
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, open-label, single-arm, multicenter study to asess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
Conditions
- Systemic Lupus Erythematosus
Interventions
Relma-celBiological
CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT rateTime frame: 3 months
- determine RP2DTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Relma-cel Medical
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.